Scutellaria Lateriflora

Scutellaria Lateriflora Whole is a non-standardized plant allergenic extract used primarily for diagnostic testing and immunotherapy in patients with specific hypersensitivities. It belongs to the class of non-standardized food and plant allergenic extracts.

Dosage for Scutellaria Lateriflora Whole is not standardized and must be individualized based on the patient's sensitivity and clinical response.

• Diagnostic Testing: For skin prick testing, a single drop of a 1:10 or 1:20 w/v (weight/volume) concentration is typically applied. For intradermal testing, 0.02 mL to 0.05 mL of a highly diluted extract (e.g., 1:1000 or 1:10,000) is injected.
• Immunotherapy (Maintenance): The dose is gradually increased from a very low starting point. A typical maintenance dose may range from 0.1 mL to 0.5 mL of the most concentrated solution tolerated by the patient, usually administered once every 1 to 4 weeks.

Scutellaria Lateriflora Whole is used in children, but dosage must be calculated with extreme caution. Pediatric patients are often more sensitive to allergenic extracts. Dosing follows the same titration principle as adults but often starts at even higher dilutions. Clinical studies have shown that immunotherapy is generally safe for children aged 5 and older, but its use in younger children must be carefully weighed by a pediatric allergist.

Renal Impairment

No specific dosage adjustments are provided for renal impairment; however, because metabolites are cleared renally, patients with Stage 4 or 5 chronic kidney disease should be monitored closely for systemic reactions.

Hepatic Impairment

Patients with severe liver disease may have altered metabolism of the flavonoid components of the extract. Caution is advised, though no formal dose-reduction protocols exist.

Elderly Patients

Geriatric patients (65+) should be assessed for underlying cardiovascular disease before administration. The risk of adverse reactions to epinephrine (used to treat potential anaphylaxis) must be considered when determining the dose of the extract.

This medication is never for self-administration at home. It must be administered by a healthcare professional in a clinic equipped with emergency resuscitation equipment.

• Administration Route: Subcutaneous injection (for immunotherapy) or epicutaneous/intradermal (for testing).
• Preparation: The vial should be inspected for particulate matter or discoloration. It should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F).
• Observation: Patients must remain in the clinic for at least 30 minutes following an injection to monitor for signs of a systemic allergic reaction.

If a dose of immunotherapy is missed, the next dose may need to be reduced depending on how much time has passed.

• < 1 week late: Continue with the scheduled dose.
• 1-2 weeks late: Maintain the previous dose level.
• > 3 weeks late: The dose may need to be reduced by one or more increments to prevent a systemic reaction.

An overdose of Scutellaria Lateriflora Whole can lead to a severe systemic allergic reaction or anaphylactic shock.

• Signs of Overdose: Rapid heart rate, difficulty breathing, widespread hives, swelling of the throat, or a sudden drop in blood pressure.
• Emergency Measures: Immediate administration of epinephrine (1:1000) intramuscularly, followed by antihistamines, corticosteroids, and IV fluids. Seek emergency medical attention immediately if these symptoms occur outside a clinical setting.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or frequency without medical guidance.

Most patients receiving Scutellaria Lateriflora Whole will experience local reactions at the site of administration. These are generally considered normal and indicate the body is responding to the allergen.

• Injection Site Redness (Erythema): A red patch around the injection site that may appear within minutes and last for several hours.
• Local Swelling (Wheal): A raised, itchy bump at the site of the injection or skin test. This typically resolves within 24 hours.
• Pruritus (Itching): Intense itching at the site of administration.

• Large Local Reactions

Scutellaria Lateriflora Whole is a potent biological agent. Its use is restricted to diagnostic and therapeutic immunological procedures. It is not for self-administration. Patients must be screened for any underlying conditions that could make an allergic reaction more dangerous, such as severe cardiovascular disease or poorly controlled asthma.

No specific FDA black box warning exists for Scutellaria Lateriflora Whole as a standalone entity, but it falls under the mandatory class warnings for Allergenic Extracts. These warnings emphasize that the extract should only be used in settings where emergency resuscitative equipment and personnel are immediately available. Fatalities have occurred with the use of allergenic extracts when administered to patients with severe asthma or when dosing errors occurred.

• Allergic Reactions / Anaphylaxis Risk

• Beta-Blockers (e.g., Propranolol, Atenolol): These medications are strictly contraindicated or used with extreme caution in patients receiving allergenic extracts. Beta-blockers can make an allergic reaction more severe and, more importantly, they can make epinephrine (the treatment for anaphylaxis) ineffective. This can lead to fatal outcomes during an emergency.

• ACE Inhibitors (e.g., Lisinopril): These may increase the risk of systemic reactions or more severe hypotension during an allergic event.
• MAO Inhibitors (e.g., Phenelzine): Due to the adrenergic agonist properties of Scutellaria Lateriflora Whole, use with MAOIs may lead to an exaggerated increase in blood pressure (hypertensive crisis).

• Severe, Uncontrolled Asthma: Patients with an FEV1 persistently below 70% of predicted values are at high risk for fatal bronchospasm during immunotherapy.
• Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The stress of a potential systemic reaction or the administration of epinephrine could be fatal.
• Hypersensitivity to Extract Components: Any known previous anaphylactic reaction to Scutellaria or the preservatives used in the extract (such as phenol or glycerin).
• Beta-Blocker Therapy: As noted, the inability to respond to epinephrine makes immunotherapy unacceptably dangerous.

Pregnancy Category C: Animal reproduction studies have not been conducted with Scutellaria Lateriflora Whole. It is not known whether the extract can cause fetal harm or affect reproduction capacity.

• Risk-Benefit: Immunotherapy is generally not started during pregnancy due to the risk of anaphylaxis, which can cause fetal hypoxia (lack of oxygen). However, if a patient is already on a maintenance dose and tolerating it well, the doctor may choose to continue the treatment at the same or a reduced dose.

It is not known whether the components of Scutellaria Lateriflora Whole are excreted in human milk. Because many botanical flavonoids and proteins can pass into milk, caution should be exercised. The risk of the infant developing a sensitivity or having a reaction is low but theoretically possible. Most experts consider immunotherapy compatible with breastfeeding.

Scutellaria Lateriflora Whole acts as an exogenous antigen. Upon administration, it cross-links IgE antibodies on the surface of mast cells and basophils. This triggers a signal transduction cascade involving tyrosine kinases, leading to the release of pre-formed mediators (histamine, tryptase) and the synthesis of newly formed mediators (leukotrienes, prostaglandins). In immunotherapy, repeated exposure to increasing doses of the extract induces a shift in the T-cell response from a Th2 (allergic) profile to a Th1 (non-allergic) profile, increases the production of Regulatory T-cells (Tregs), and stimulates the production of IgG4 'blocking' antibodies.

The specific Ammonium Ion Binding Activity and Adrenergic Agonist properties suggest that components of the whole plant (likely the alkaloids and flavonoids) interact with metabolic pathways and the autonomic nervous system, though these are secondary to its primary immunological function.

• Onset of Action (Testing)